logo-loader

Buds & Duds: Cannabis stocks show strong finish to 2019

Most of the big name cannabis stocks were trading demonstrably higher on New Year’s Eve

cannabis plants
Blue skies for cannabis investors in 2020?

Cannabis stocks had a strong finish to the year, and the decade, with all major indices seeing a boost across North America. 

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was up 7% at 118.4 points. Elsewhere, the Horizons Marijuana Life Sciences Index ETF also gained 7% at C$8.74, while the OTCQX Cannabis index rose 4.3% to 462.6 points. 

Buds  

Most of the big name cannabis stocks were trading demonstrably higher on New Year’s Eve. 

Canopy Growth Corporation (TSE:WEED) (NYSE:CGC) surged around 12% in both Canada and the US at C$27.50 and US$21.01 on Friday afternoon, while Aurora Cannabis Inc (TSE:ACB) (NYSE:ACB) rocketed 12.8% in Canada and 12.3% in the US at C$2.81 and US$2.14 respectively.   

US operator Cronos Group Inc (TSE:CRON) (NASDAQ:CRON) was also strong, up 16.1% at C$10.02 and 17.3% at US$7.77. 

On the small cap front, Enwave Corporation (CVE:ENW) (OTCMKTS:NWVCF) was also higher on Tuesday after it signed an equipment purchase agreement with food processing company Consulting FB Tech and Apps SL in Peru for the delivery of one of its 100 kiloWatt Radiant Energy Vacuum (REV) machines.  

The company, which operates under the name Fresh Business, plans to scale up its operations in Peru, where it sources its fruits and vegetables to be dehydrated with EnWave’s technology. 

Shares of Enwave gained 8.2% in Toronto at C$1.59 and 8% over the counter at US$1.22. 

Duds 

MediPharm Labs Corp (TSE:LABS) (OTCMKTS:MEDIF) was pulling up the rear on Tuesday afternoon, down 1.5% in Toronto at C$3.86. On Monday the company said it had received approval to expand its Barrie, Ontario facility for private label and white label production and R&D. 

Contact Angela at [email protected] 

Follow her on Twitter @AHarmantas 

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Genprex sees newly licensed diabetes gene therapy as an...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based biotech has signed a licensing agreement with the University of Pittsburgh for a diabetes gene therapy that could have the potential to treat Type 1 and Type 2 diabetes. Varner says the newly licensed diabetes gene...

2 days, 10 hours ago

2 min read